Any price prediction for ARVN?

**Arvinas (ARVN) is poised for a bullish outlook**, with several indicators suggesting potential for price appreciation. Here's a detailed analysis:

1. **Current Trend**: The stock is experiencing a **bullish trend**, which has lasted for 44 days. The probability of this trend continuing is 25%, with 37 days showing a clear bullish signal and 7 days of uncertainty.

2. **Support and Resistance Levels**: ARVN is currently positioned **between narrow support and wide support levels**, as well as **between narrow and wide resistance levels**. The stock is considered **bearish** in this context.

3. **Forecast Price**: The price forecast for ARVN shows a **bullish outlook**, with a mean forecast price of $7.62 on July 17, 2025, ranging from $7.46 to $7.7 over the next few days. The forecast for July 23, 2025, is $7.77, indicating a potential peak before a possible pullback.

4. **Market Sentiment**: Despite the CEO's retirement, which could have led to uncertainty, the market has responded positively, with the stock surging by 2.62% on the news of the CEO's retirement. This suggests that investor confidence is high, especially given the potential for vepdegestrant to become the first approved treatment for ESR1-mutant patients.
5. **Analyst Ratings**: Several analysts have reaffirmed a Buy rating on ARVN, citing the potential of vepdegestrant and the company's undervaluation. This sentiment is reflected in the forecast performance, which shows an expected maximum gain of 16.79% with a potential maximum loss of -7.81%.

In conclusion, ARVN presents a favorable risk-reward scenario, with a strong likelihood of price appreciation. Investors should consider these factors when evaluating their investment strategy for ARVN.